Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
During the 2025 EURETINA congress, the Eye Care Network spoke with Mark Gillies, MD, PhD, director of research at the Save Sight Institute, about anti-VEGF agents.
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
Related Content
An elderly woman with glasses sits on a grassy hillside, near a tranquil blue lake. Concept image for geographic atrophy and vision-related quality of life measures. ©CameraCraft – stock.adobe.com

Intravitreal complement inhibitor treatment for GA viewed favorably by patients

Lynda Charters
October 7th 2025
Article
MacuMira launches first Health Canada-approved device for AMD treatment

MacuMira launches first Health Canada-approved device for AMD treatment

Kassi Filkins
October 7th 2025
Article
A hand writes a check mark in a box. It is superimposed over an image of samples in a laboratory. Image credit: ©everythingpossible – stock.adobe.com

European Commission grants marketing authorisation to aflibercept biosimilar EYLUXVI (ALT-L9)

Martin David Harp
October 7th 2025
Article
A movie theatre with empty seats. The screen has reels of film negatives, with a blue tint, and the words "Coming Soon" in large yellow letters. Image credit: Created with Canva. Components via Photology2000 and Ron Lach, Pexels.

EURETINA industry previews: Beacon Therapeutics, Nanoscope Therapeutics and Valitor

Kassi Filkins
October 7th 2025
Article
An older woman with glasses on sits and reads a book, a mug of coffee in front of her. Concept image for geographic atrophy lesions (GA) and age-related macular degeneration (AMD). Image credit: ©MiguelAngel – stock.adobe.com

Progression rates vary in subtypes of geographic atrophy lesions

Lynda Charters
October 7th 2025
Article
A mesh wire trash can with lots of wadded-up pieces of paper in it. Some of the pieces of paper have visible drawing. DNA helixes are drawn on some of the pieces of wadded-up paper. Concept image for gene therapy, age-related macular degeneration and new approach to AMD treatment. Image created with Canva AI Magic Media.

Starting from scratch on neovascular age-related macular degeneration

Lynda Charters
October 7th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.